SEC 13F Intelligence

Rtw Investments, LP / MLTX

Rtw Investments, LP’s Moonlake Immunotherapeutics Position

Does Rtw Investments, LP own Moonlake Immunotherapeutics (MLTX)? Not currently — the last reported position was 741.1K shares worth $35M in Q2 2025; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$35M
Q2 2025
Shares
741.1K
% of Portfolio
+0.50%
Quarters Held
7
position exited

Position History MLTX

Reported value by quarter
Q2 ’22: $3MQ2 ’22Q3 ’22: $4MQ3 ’22Q4 ’22: $5MQ4 ’22Q1 ’23: $11MQ1 ’23Q2 ’23: $26MQ2 ’23Q3 ’23: $29MQ3 ’23Q2 ’25: $35MQ2 ’25filingsflow.com
QuarterSharesValue% of Portfolio
Q2 2025741.1K$35M+0.50%
Q3 2023500.0K$29M+0.60%
Q2 2023500.0K$26M+0.49%
Q1 2023500.0K$11M+0.22%
Q4 2022500.0K$5M+0.11%
Q3 2022500.0K$4M+0.09%
Q2 2022500.0K$3M+0.07%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Rtw Investments, LP’s full portfolio or all institutional holders of MLTX.